Abivax SA (FR:ABVX)
:ABVX
Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€104.70
-€0.19(-2.81%)
At close: 4:00 PM EST
€104.70
-€0.19(-2.81%)
Day’s Range― - ―
52-Week Range€5.00 - €132.00
Previous CloseN/A
Volume4.35K
Average Volume (3M)99.97K
Market Cap
€7.61B
Enterprise Value€7.18B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€32.09M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Jun 08, 2026EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding79,291,190
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.45
Revenue Forecast (FY)€3.49M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetA materially stronger 2025 balance sheet with debt around 7% of equity and sharply higher equity reduces near-term refinancing risk. This durable capital buffer gives management flexibility to fund multi-year clinical programs, pursue partnerships, and absorb trial timing variability without immediate dilution.
Focused Clinical PipelineAbivax’s business model centers on R&D with a clear lead candidate (ABX464) targeting chronic inflammatory diseases. A focused pipeline concentrates resources, clarifies regulatory and commercialization strategy, and can attract partner or licensing interest, improving chances of durable value capture if trials succeed.
High Historical Gross MarginsNear-100% gross margins historically indicate attractive product economics once commercialized or licensed. Such high incremental margins imply scalable profitability potential, strong leverage to revenue growth, and favorable economics for future partnerships or commercialization if clinical success is achieved.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows (2020–2025) and a ~-162M FCF in 2025 mean the business cannot self-fund development. Long-term dependence on external capital raises increases dilution risk, constrains strategic optionality, and elevates execution risk for multi-year clinical programs.
No Commercial Revenue; Widening LossesWidening net and operating losses combined with revenue falling to zero in 2025 leave the company without commercial validation or internal funding sources. This structural lack of revenue makes long-term viability contingent on trial outcomes and external financing rather than on operational cash generation.
History Of Balance Sheet SwingsPrior periods of very high leverage and sizeable balance-sheet swings show the company has historically relied on capital raises and restructuring. That pattern signals recurring financing risk and potential dilution, reducing predictability of funding and increasing the execution burden on management over the medium term.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €5.00 and its highest was €132.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €7.61B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Jun 08, 2026 which is in 41 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on Mar 23, 2026. The company reported -€1.04 earnings per share for the quarter, beating the consensus estimate of -€1.161 by €0.121.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.8.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,291,190 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€1.04 in its last earnings report, beating expectations of -€1.161. Following the earnings report the stock price went down -3.755%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
€125.00
▲(19.39% Upside)
Technical Analysis
Options Prices
Currently, No data available
---